Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Peterlabs Holdings Bhd's Debt-to-Equity or its related term are showing as below:
XKLS:0171's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.275 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Peterlabs Holdings Bhd Debt-to-Equity Related Terms
Peterlabs Holdings Bhd Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Peterlabs Holdings Bhd's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0171 vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd (XKLS:0171) has a Debt-to-Equity of 0.25 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Peterlabs Holdings Bhd and its competitors.
Is Peterlabs Holdings Bhd's Debt-to-Equity too high?
Peterlabs Holdings Bhd's current Debt-to-Equity is 0.25. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Peterlabs Holdings Bhd's value of 0.25 is 9.1% below this industry median. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's Debt-to-Equity compare to ZTS and UTHR?
Peterlabs Holdings Bhd's Debt-to-Equity of 0.25 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. Peterlabs Holdings Bhd's value of 0.25 is 9.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Peterlabs Holdings Bhd's current Debt-to-Equity of 0.25 is 9.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current Debt-to-Equity is 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Peterlabs Holdings Bhd (XKLS:0171) has a current Debt-to-Equity of 0.25. The current Debt-to-Equity is 0.25 and 9.1% below the Drug Manufacturers industry median of 0.28. Peterlabs Holdings Bhd's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current Debt-to-Equity is 0.25 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
